The Phase 3 sunRIZE study did not meet its primary or key secondary endpoints, though some biomarker and CGM signals were observed. The company is pursuing FDA regulatory pathway discussions and has an ongoing Phase 3 tumor hyperinsulinism (upLIFT) study with topline data expected in H2 2026, positioning itself in the ultra-rare metabolic disease treatment space.
Cyborg Score Rationale
The Phase 3 sunRIZE study did not meet its primary or key secondary endpoints. The company faces significant clinical and regulatory headwinds following trial failure, though it retains cash reserves and continues development in tumor hyperinsulinism indication.
Top Insights
Phase 3 sunRIZE study in congenital hyperinsulinism failed primary and key secondary endpoints
Cash position of $132.9M as of December 31, 2025
Tumor HI upLIFT enrollment ongoing with topline data expected H2 2026
Company pursuing FDA discussions under Breakthrough Therapy Designation to reassess regulatory strategy post-trial failure
Named Competitors
Gene therapy and insulin modulators — Alternative approaches to hyperinsulinism treatment
Recent Developments
(February 2026) Phase 3 sunRIZE results showed failure to meet primary endpoints; upLIFT tumor HI study ongoing
(January 2026) Company shared Expanded Access Program outcomes and announced FDA meeting under Breakthrough Therapy Designation
(December 2025) sunRIZE study results announcement triggered significant stock decline
Open the full interactive Rezolute, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.